AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025)
AbCellera Biologics (ABCL) posted Non-Current Deffered Revenue of $5.8 million for Q3 2025, down 49.71% on a QoQ basis from $11.6 million in Q2 2025, and down 27.78% year-over-year from $8.1 million in Q3 2024.
AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
AbCellera Biologics' Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $5.8 million for Q3 2025.
- Quarterly Non-Current Deffered Revenue fell 27.78% year-over-year to $5.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.8 million (down 27.78% YoY) and the FY2024 annual result came in at $5.7 million, down 30.45% from the prior year.
- Non-Current Deffered Revenue was $5.8 million for Q3 2025 at AbCellera Biologics, down from $11.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $64.8 million in Q2 2022 and bottomed at $5.7 million in Q4 2024.
- A 5-year average of $27.0 million and a median of $19.5 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 123.29% — and 2023, when it tumbled 73.66%.
- AbCellera Biologics' Non-Current Deffered Revenue stood at $27.4 million in 2021, then decreased by 28.8% to $19.5 million in 2022, then slumped by 58.01% to $8.2 million in 2023, then tumbled by 30.45% to $5.7 million in 2024, then climbed by 2.63% to $5.8 million in 2025.
- Business Quant data shows ABCL's Non-Current Deffered Revenue at $5.8 million in Q3 2025, $11.6 million in Q2 2025, and $13.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.85 Mn |
| Jun 30, 2025 | 11.63 Mn |
| Mar 31, 2025 | 13.75 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Sep 30, 2024 | 8.10 Mn |
| Jun 30, 2024 | 7.97 Mn |
| Mar 31, 2024 | 8.57 Mn |
| Dec 31, 2023 | 8.20 Mn |
| Sep 30, 2023 | 16.38 Mn |
| Jun 30, 2023 | 27.72 Mn |
| Mar 31, 2023 | 25.42 Mn |
| Dec 31, 2022 | 19.52 Mn |
| Sep 30, 2022 | 62.20 Mn |
| Jun 30, 2022 | 64.80 Mn |
| Mar 31, 2022 | 64.15 Mn |
| Dec 31, 2021 | 27.41 Mn |
| Sep 30, 2021 | 59.68 Mn |
| Jun 30, 2021 | 46.62 Mn |
| Mar 31, 2021 | 28.73 Mn |
| Dec 31, 2020 | 25.89 Mn |